CG Oncology Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CGON research report →
Range $97 – $113
Price Chart
About the company
CG Oncology, Inc. , a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
- CEO
- Arthur Kuan
- IPO
- 2024
- Employees
- 142
- HQ
- Dallas, TX, US
Get TickerSpark's AI analysis on CGON
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.10B
- P/E
- -28.88
- Fwd P/E
- 25.30
- PEG
- 1.00
- P/S
- 1158.86
- P/B
- 7.17
- EV/EBITDA
- -30.49
- Div Yield
- 0.00%
- Gross Margin
- -102.24%
- Op Margin
- -4293.53%
- Net Margin
- -3851.09%
- ROE
- -24.58%
- ROIC
- -26.44%
Latest fiscal year · YoY change
- Revenue
- $4.04M+254.7%
- Gross Profit
- $-607,000+99.3%
- Op Income
- $-190,774,000
- Net Income
- $-160,995,000-82.9%
- EPS
- $-2.08-47.5%
- OCF Growth
- -68.1%
- FCF Growth
- -67.8%
- 52W High
- $93.95
- 52W Low
- $37.01
- 50D MA
- $68.71
- 200D MA
- $67.25
- Beta
- 0.24
- RSI (14)
- 64
- Avg Volume
- 1.22M
No earnings-call transcripts are available for CGON yet.
- Free Float
- 77.2%
- Shares Outstanding
- 89.32M
- Float Shares
- 68.95M
of shares held by institutions
248 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rtw Investments, LP | 8.51M | 0 |
| T. Rowe Price Investment Management, Inc. | 6.73M | ▲ 110.05K |
| Vanguard Group Inc | 6.54M | ▼ 37.80K |
| Decheng Capital LLC | 6.37M | 0 |
| Blackrock, Inc. | 6.35M | ▲ 91.05K |
| Wellington Management Group Llp | 4.92M | ▼ 407.67K |
| Fmr LLC | 4.59M | ▲ 432.97K |
| Tcg Crossover Management, LLC | 3.67M | 0 |
| Vanguard Capital Management LLC | 3.57M | ▲ 257.24K |
| Vanguard Portfolio Management LLC | 3.52M | ▲ 50.42K |
| State Street Corp | 3.23M | ▼ 203.71K |
| Price T Rowe Associates Inc | 3.11M | ▼ 699.23K |
Held by 431 ETFs
Biggest fund positions in CGON by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Kuan Arthur | buy | 30,000.32 |
| Nov 18, 26 | Kalofonos Isabel | buy | 3,751 |
| Nov 16, 26 | POST LEONARD E | other | 1,000 |
| Nov 16, 26 | POST LEONARD E | other | 1,000 |
| Nov 16, 26 | POST LEONARD E | sell | 1,000 |
| Oct 15, 26 | Kalofonos Isabel | other | 92,000 |
| Oct 15, 26 | POST LEONARD E | other | 1,000 |
| Oct 15, 26 | POST LEONARD E | other | 1,000 |
| Oct 15, 26 | POST LEONARD E | sell | 500 |
| Oct 15, 26 | POST LEONARD E | sell | 500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CGON coverage
Recent articles, reports, and earnings notes.
No research on CGON yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CGON report →CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds
benzinga.com · Nov 16
2 Cancer-Drug Developers Seeing Unusual Options Volume
schaeffersresearch.com · Nov 16
CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out
investors.com · Nov 16
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
globenewswire.com · Nov 16
CG Oncology, Inc. $CGON Stock: Candriam S.C.A. Cuts Position
defenseworld.net · Nov 9
CG Oncology, Inc. (CGON) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 6
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com · Nov 6
CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy
seekingalpha.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.